Innovative antifibrotic therapies in systemic sclerosis

Area of Science:

• Fibrosis research
• Translational medicine
• Systemic sclerosis (SSc) treatment

Background:

• Fibrosis, characterized by excessive collagen release from activated fibroblasts, is a hallmark of systemic sclerosis (SSc).
• SSc-related fibrosis significantly contributes to disease morbidity and mortality, with limited effective clinical treatments currently available.
• Emerging translational studies offer promising antifibrotic agents, some progressing into clinical trials.

Purpose of the Study:

• To review recent advancements in antifibrotic treatment strategies for SSc.
• To highlight targeted therapeutic approaches with proven efficacy and tolerability in preclinical SSc models or clinical evaluation.
• To discuss a range of candidate antifibrotic therapies targeting key fibrotic pathways.

Main Methods:

• Focus on recent advances in antifibrotic therapy development for SSc.
• Selection of targeted therapies demonstrating high efficacy and tolerability in preclinical SSc models and/or clinical trials.
• Discussion of candidate therapies including those blocking inflammatory pathways, inhibiting profibrotic growth factors, modulating epigenetic signaling, and interfering with morphogenic pathways.

Main Results:

• Numerous antifibrotic candidate therapies exhibit significant efficacy and good tolerability in preclinical SSc models.
• A limited number of these promising agents have been evaluated in early-phase clinical studies.
• Candidate therapies target diverse mechanisms including inflammation, growth factor signaling, epigenetics, and morphogenic pathways.

Conclusions:

• Many antifibrotic agents show potential for treating SSc fibrosis based on preclinical data.
• Clinical translation of these findings into effective SSc treatments remains a critical challenge.
• Future research must prioritize translating novel molecular strategies into clinical practice for SSc patients.